SCHEMBL399855

SCHEMBL399855

CS(=O)(=O)Nc1cccc(N)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.61
KEAP1 Q14145 1/20 0.57
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TYRO3 Q06418 1/20 0.55
POLB P06746 2/20 0.53
DDX3X O00571 1/20 0.50
KIF11 P52732 1/20 0.49
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
GFER P55789 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
KDM1A O60341 1/20 0.48
NR3C1 P04150 1/20 0.47
BRD4 O60885 1/20 0.46
HSD17B1 P14061 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29794834 1.00 HTR6 (0.61) HTR6KEAP1ALDH1A1SMN1; SMN2TYRO3
SCHEMBL698855 0.85 KEAP1 (0.70) KEAP1ALDH1A1SMN1; SMN2POLBKIF11
SCHEMBL10138631 0.85 HTR6 (0.57) HTR6ALDH1A1SMN1; SMN2TYRO3POLB
SCHEMBL8547020 0.82 HTR6 (0.62) HTR6ALDH1A1POLBDDX3XKDM4E
SCHEMBL11655851 0.81 HTR6 (0.57) HTR6ALDH1A1SMN1; SMN2POLBDDX3X
SCHEMBL12728616 0.80 HTR6 (0.61) HTR6ALDH1A1SMN1; SMN2POLBDDX3X
SCHEMBL27861796 0.80 HTR6 (0.61) HTR6ALDH1A1SMN1; SMN2POLBDDX3X
SCHEMBL16181301 0.80 HTR6 (0.51) HTR6ALDH1A1SMN1; SMN2TYRO3POLB
SCHEMBL31604298 0.80 HTR6 (0.61) HTR6ALDH1A1SMN1; SMN2POLBDDX3X
SCHEMBL2446287 0.79 HTR6 (0.56) HTR6ALDH1A1POLBDDX3XKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109096152-B Preparation method of m-methanesulfonamido aniline 乐平市赛复乐医药化工有限公司 2021-01-08 CN claimed
CN-108299250-B Continuous preparation method of m-dialkylaminomethylsulfonylanilide 江苏迪安化工有限公司 2020-09-18 CN claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP claimed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US claimed
US-8354444-B2 Substituted pyrrolidine-2-carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-01-15 US claimed
EP-2340021-B1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2012-11-07 EP claimed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 WO claimed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
WO-2025217141-A1 PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 ENANTA PHARMACEUTICALS, INC. (US) 2025-10-16 WO disclosed
US-20250313569-A1 Pharmaceutical Compounds And Compositions As Modulators Of MAS-Related G-Protein Receptor X2 ENANTA PHARMACEUTICALS, INC. 2025-10-09 US disclosed
US-4025614-A Substituted 2H-pyran-2,6 (3H)-dione derivatives useful in treatment of allergic reactions SMITHKLINE CORPORATION (US) 1977-05-24 US disclosed
US-3978040-A Process for the preparation of cyanoazo compounds by reacting halogenoazo compounds with CuCN in an aqueous media in the presence of a nitrogen base BAYER AKTIENGESELLSCHAFT (DT) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313569-A1 Pharmaceutical Compounds And Compositions As Modulators Of MAS-Related G-Protein Receptor X2 MRGPRX2, MRGPRX1, MRGPRX4 HTR6 673/4885KEAP1 1655/4885ALDH1A1 4719/4885
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 HTR6 3828/4885KEAP1 3810/4885ALDH1A1 2027/4885
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 HTR6 3828/4885KEAP1 3810/4885ALDH1A1 2027/4885
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS HTR6 4016/4885KEAP1 765/4885ALDH1A1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.